AI, Rare Disease Research, and the Risks of “Synthetic Patients”
Artificial intelligence (AI) is beginning to find its place in rare disease research. With small populations, fragmented[…]
5 Misconceptions About Patient Engagement in JCA – And Why Early Access Could Be Your Advantage
As EU HTA evolves under the Joint Clinical Assessment (JCA), the expectations for structured, regulator-ready patient engagement[…]
5 Patient Evidence Myths That Could Undermine Your EU JCA Strategy
The bar for patient evidence in EU health technology assessment (HTA) is rising fast. As the Joint Clinical[…]
Using PICO to Build Stronger Evidence in Rare Disease Advocacy
Supporting structured, independent patient input in the EU JCA era The European Joint Clinical Assessment (JCA) is[…]
How Digital Patient Insights Can Strengthen Your EU HTA Submission
The EU Joint Clinical Assessment (JCA) represents a significant shift in the regulatory landscape for companies developing[…]
Why Patient Voices Are Critical for EU Joint Clinical Assessment (JCA) Now
The European Union is in the midst of a transformative shift toward a harmonized Health Technology Assessment[…]
Making Patient Partnership a Reality in EU Joint Clinical Assessment (JCA)
Introduction: As the EU’s Joint Clinical Assessment (JCA) system rapidly evolves, patient involvement is no longer a[…]
Early Access Strategies to Boost EU Joint Clinical Assessment (JCA) Readiness
Early Access – A Strategic Edge for JCA Readiness As the EU Joint Clinical Assessment (JCA) framework[…]
Patient Engagement in the 110-Day EU Joint Clinical Assessment (JCA) Sprint
From 12 January 2028, every EU orphan-designated therapy must navigate a 110-day Joint Clinical Assessment (JCA) timeline[…]